Welcome to the ADAKVEO® On-demand webinars page. Below you can access the latest educational webinars organised by Novartis and hosted by experts in the field of haematology.
You will be required to register to watch the videos.
TURNING THE TIDE: REVOLUTIONISING SCD MANAGEMENT
In this webinar, Dr Julie Kanter, the Co-Director of the Comprehensive Sickle Cell Centre at the University of Alabama at Birmingham, United States, shares her first-hand experience of ADAKVEO® (crizanlizumab) and how it has been integrated into clinical practice. Dr Kanter shares her clinical experience that shows the meaningful difference ADAKVEO® can make to patients with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOC), as well as providing her recommendations on how to promote adherence.
Watch the Novartis webinar which took place on September 23rd, 2021.
SICKLE CELL DISEASE: MODERN MANAGEMENT OF A NEOLITHIC DISEASE
Dr Martin Besser, and clinical nurse specialists Vivian Garcia and Ruth Jolley, lead an interesting webinar featuring an overview of the pathophysiology of sickle cell disease (SCD), the impact of vaso-occlusive crises (VOC) and what this means for patients. The faculty also covered prevention and treatment of VOCs, including new therapies in their SCD centre. They concluded by presenting case studies sharing their own experience treating patients and administering these treatments in the growing centre at Addenbrooke’s Hospital, Cambridge.
Click below to watch the clip from the Novartis webinar which took place on June 22nd, 2021.
THE BURDEN OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE
In this symposium from BSH 2021, Consultant Haematologist Professor Jo Howard takes a look at the pathophysiology of sickle cell disease (SCD) and the impact that vaso-occlusive crises have on all aspects of patient’s lives. She offers management strategies for pain associated with SCD and evaluates some of the emerging therapies as of April 2021.
Indication: ADAKVEO® is indicated for the prevention of recurrent VOCs in SCD patients aged 16 years and older. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1
ADAKVEO® has conditional marketing authorisation and further evidence is awaited.
SCD, sickle cell disease; VOC, vaso-occlusive crisis.
- ADAKVEO® Summary of Product Characteristics, 2021.